Recent Finacing
Recent Raise
Siamab Therapeutics develops monoclonal antibodies targeting tumor-associated carbohydrate antigens (TACAs), leveraging a UCSD-licensed glycobiology platform, conducting San Diego preclinical in vivo work and IND-enabling studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors